Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Biomea Fusion (Nasdaq: BMEA) announced an inducement equity award granted by its compensation committee on November 26, 2025. One new employee received non-qualified stock options to purchase 7,500 shares of common stock under the company’s 2023 Inducement Equity Plan. Shares vest at 1/16 per quarter over four years, subject to continued employment. The award was granted as an inducement material to the employee entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan was adopted by the board on November 17, 2023.

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase 7,500 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to such employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).

The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.

About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
  
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. 

Contact:  
Meichiel Jennifer Weiss  
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com  

FAQ

What did Biomea Fusion (BMEA) grant on November 26, 2025?

Biomea granted one new employee non-qualified stock options to purchase 7,500 shares of common stock.

How do the Biomea (BMEA) stock options vest?

The options vest 1/16 per quarter over four years, subject to continued employment.

Under which plan were the Biomea (BMEA) options granted?

The award was made under the company’s 2023 Inducement Equity Plan adopted November 17, 2023.

Why was the Biomea (BMEA) award classified as an inducement?

It was granted as an inducement material to the employee entering employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Does the announcement report any cash payment or additional financial terms for BMEA?

No cash amounts or additional financial terms beyond the 7,500-share option grant and vesting schedule were disclosed.